Search Patents
  • Substituted Heteroaryls
    Publication number: 20130165452
    Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 27, 2013
    Applicant: PFIZER INC.
    Inventor: Pfizer Inc.
  • QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
    Patent number: 6384039
    Abstract: A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: May 7, 2002
    Assignee: Pfizer Inc.
    Inventor: Anthony A. Fossa
  • Imidazole compounds as transforming growth factor (TGF) inhibitors
    Patent number: 7635702
    Abstract: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: December 22, 2009
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Imidazopyrimidines as transforming growth factor (TGF) inhibitors
    Patent number: 7417041
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 26, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Dihydropyrimidine antiallergy agents
    Patent number: 5250531
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: October 5, 1993
    Assignee: Pfizer Inc.
    Inventor: Kelvin Cooper
  • Methods for treating osteoarthritis using an estrogen agonist/antagonist
    Publication number: 20040157862
    Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.
    Type: Application
    Filed: January 22, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventor: Bruce H. Littman
  • Selective inhibitors of cyclooxygenase-2
    Publication number: 20030207897
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: 1
    Type: Application
    Filed: April 16, 2003
    Publication date: November 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040259887
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: May 13, 2004
    Publication date: December 23, 2004
    Applicant: Pfizer Inc
    Inventor: Robert L. Dow
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040077650
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: October 6, 2003
    Publication date: April 22, 2004
    Applicant: Pfizer Inc.
    Inventor: Robert L. Dow
  • Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
    Publication number: 20040152713
    Abstract: The present invention provides methods, pharmaceutical compositions and kits for treating joint pain and/or improving sleep using a SERM of formula (I): 1
    Type: Application
    Filed: January 21, 2004
    Publication date: August 5, 2004
    Applicant: Pfizer Inc.
    Inventor: Charles D. Petrie
  • Pharmaceutical formulations containing voriconazole
    Patent number: 6632803
    Abstract: The invention provides pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a sulfobutylether &bgr;-cyclodextrin.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: October 14, 2003
    Assignee: Pfizer Inc
    Inventor: Valerie Denise Harding
  • 3-Benzhydrylidene-8-aza-bicyclo[3.2.1]octane derivatives with opioid receptor activity
    Publication number: 20040254190
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: April 14, 2004
    Publication date: December 16, 2004
    Applicant: Pfizer Inc
    Inventor: Spiros Liras
  • Diaryl compounds
    Patent number: 6800652
    Abstract: The invention relates to compounds of formula I
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: October 5, 2004
    Assignee: Pfizer Inc.
    Inventors: Mark David Andrews, David Hepworth, Donald Stuart Middleton
  • Benzofuranyl derivatives
    Patent number: 8735396
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: May 27, 2014
    Assignee: Pfizer Inc.
    Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
  • Benzofuranyl derivatives
    Patent number: 8455496
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: June 4, 2013
    Assignee: Pfizer Inc.
    Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
  • Bicyclic compounds
    Patent number: 6248753
    Abstract: This invention relates to compounds of the formula wherein A, B, R3, R4, R5 and R7 are as defined herein, and to their use in the treatment of stress-related diseases.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • Enzymatic resolution of selective estrogen receptor modulators
    Patent number: 7351567
    Abstract: The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: April 1, 2008
    Assignee: Pfizer Inc.
    Inventor: Kevin K. Liu
  • Substituted6,6-hetero-bicyclicderivatives
    Patent number: 6875769
    Abstract: This invention relates to compounds of the formula wherein A, B, D, E, K, G, R3 and R5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: April 5, 2005
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Substituted heterocyclic derivatives
    Patent number: 6525067
    Abstract: CRF antagonists of Formulas I-V, wherein the B group in the Formulas contains an oxime The variables in the Formulas have the meanings described herein.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: February 25, 2003
    Assignee: Pfizer Inc
    Inventor: Yuhpyng Chen
  • Use of naphthalene derivatives in treating lung carcinoma
    Patent number: 5821245
    Abstract: A method of inhibiting cell growth in human small cell lung carcinoma comprising administering to a mammal in need of such treatment a cell growth inhibitory amount of a compound of the formula ##STR1##
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: October 13, 1998
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard, Jr.